Compare Amphastar Pharmaceuticals Inc (AMPH) vs Rex Fang & Innovation Equity Premium Income ETF (FEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Rex Fang & Innovation Equity Premium Income ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.04 (market cap $868.62M), while Rex Fang & Innovation Equity Premium Income ETF trades at $41.8. The key difference: Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | FEPI | |
|---|---|---|
Market Cap | $868.62M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $30.81 | $49.54 |
52-Week Low | $16.87 | $37.98 |
Enterprise Value | $1.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.98, down 1.62% today, with a bullish technical signal supported by moving averages. The company reported mixed Q2 2026 results, beating EPS estimates with $0.91 versus $0.62 expected, but revenue growth remains modest. Valuation ratios appear reasonable with P/E of 12.08 and P/S of 1.3, while profitability metrics show a net income margin of 10.76% and ROE of 10.3%.
The outlook is balanced with analyst consensus leaning Hold (66.67%) amid regulatory scrutiny and competitive pressures. Near-term catalysts include pipeline developments, but risks from FDA warnings and generic drug tariff uncertainties warrant caution. Cash flow trends improved with 2026 net cash flow projected at $36 million.
FEPI trades at $41.80, showing slight daily weakness with a 0.17% decline. The ETF maintains a bullish technical signal with strong moving average support and weekly dividend distributions averaging $0.20-0.21. Recent news highlights FEPI's aggressive covered call strategy targeting AI and mega-cap tech names to generate its 25% yield, though analysts caution about NAV erosion risks during market downturns.
The outlook remains cautiously optimistic given the bullish technical setup and high income generation, but investors face significant risk from the concentrated tech portfolio and covered call strategy that limits upside potential. Market sentiment is divided between yield-seeking investors and those concerned about long-term NAV preservation in volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →
